Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2025)

Apimeds Pharmaceuticals US has reported Cash & Equivalents for 3 years, with the latest figure at $1.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 47270.62% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (up 47270.62% YoY), and the FY2025 full-year result was $1.6 million, up 47270.62% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $1.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $8.7 million in Q2 2025, with the low at $3455.0 in Q4 2024.
• Historically, Cash & Equivalents has averaged $3.0 million across 3 years, with a median of $1.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 99.16% — and 2025, when it surged 47270.62%.
• Apimeds Pharmaceuticals US's Cash & Equivalents stood at $410481.0 in 2023, then plunged by 99.16% to $3455.0 in 2024, then surged by 47270.62% to $1.6 million in 2025.
• The last three Cash & Equivalents figures came in at $1.6 million (Q4 2025), $7.0 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.